Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer

Topics in Magnetic Resonance Imaging

Volumn 19, Issue 6, 2008, Pages 261-272

  Jacobs, Michael A ^a   Ouwerkerk, Ronald ^a   Petrowski, Kyle ^a   MacUra, Katarzyna J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CITRIC ACID; CREATININE; CONTRAST MEDIUM; CREATINE; TUMOR MARKER;

ADULT; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EX VIVO STUDY; HUMAN; IN VIVO STUDY; MALE; METABOLITE; METASTASIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; WHOLE BODY MRI; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; MATHEMATICS; METABOLISM; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

CHOLINE; CITRATES; CONTRAST MEDIA; CREATINE; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MATHEMATICS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; WHOLE BODY IMAGING;

EID: 68049121906     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e3181aa6b50     Document Type: Review

References (147)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
3. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol. 1989;141:1136-1138.
4. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290.
5. Clark TW, Goldenberg L, Cooperberg PL, et al. Stratification of prostate-specific antigen level and results of transrectal ultrasonography and digital rectal examination as predictors of positive prostate biopsy. Can Assoc Radiol J. 1997;48:252-258.
6. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50:125-128.
7. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243:28-53.
8. Cornfeld DM, Weinreb JC. MR imaging of the prostate: 1.5T versus 3T. Magn Reson Imaging Clin N Am. 2007;15:433-448.
9. Macura KJ. Multiparametric magnetic resonance imaging of the prostate: current status in prostate cancer detection, localization, and staging. Semin Roentgenol. 2008;43:303-313.
10. Bonekamp D, Macura KJ. Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate. Top Magn Reson Imaging. 2008;19:273-284.
11. Schnall MD, Lenkinski RE, Pollack HM, et al. Prostate: MR imaging with an endorectal surface coil. Radiology. 1989;172:570-574.
12. Beyersdorff D, Taymoorian K, Knosel T, et al. MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR Am J Roentgenol. 2005;185:1214-1220.
13. Hricak H, Williams RD, Spring DB, et al. Anatomy and pathology of the male pelvis by magnetic resonance imaging. AJR Am J Roentgenol. 1983;141:1101-1110.
14. Schiebler ML, Tomaszewski JE, Bezzi M, et al. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Radiology. 1989;172:131-137.
15. Schiebler ML, Schnall MD, Pollack HM, et al. Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology. 1993;189:339-352.
16. Kier R, Wain S, Troiano R. Fast spin-echo MR images of the pelvis obtained with a phased-array coil: value in localizing and staging prostatic carcinoma. AJR Am J Roentgenol. 1993;161:601-606.
17. Tempany CM, Zhou X, Zerhouni EA, et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology. 1994;192:47-54.
18. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal - pelvic phased-array coils. Radiology. 1994;193: 703-709.
19. Liney GP, Lowry M, Turnbull LW, et al. Proton MR T2 maps correlate with the citrate concentration in the prostate. NMR Biomed. 1996; 9:59-64.
20. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am. 2000;38:59-85, viii.
21. Miller D, Hafez K, Stewart A, et al. Prostate carcinoma presentation, diagnosis, and staging. Cancer. 2003;98:1169-1178.
22. Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging. 2005;22:639-646.
23. Park BK, Kim B, Kim CK, et al. Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. J Comput Assist Tomogr. 2007;31:534-538.
24. Moseley ME, Kucharczyk J, Mintorovitch J, et al. Diffusion-weighted MR imaging of acute stroke: correlation withT2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol. 1990;11:423-429.
25. Mintorovitch J, Moseley M, Chileuitt L, et al. Comparison of diffusion and T2 weighted MRI for the early detection of cerebral ischemia and reperfusion in rats. Magn Reson Med. 1991;18:39-50.
26. Castillo M, Arbelaez A, Smith JK, et al. Diffusion-weighted MR imaging offers no advantage over routine noncontrast MR imaging in the detection of vertebral metastases. AJNR Am J Neuroradiol. 2000;21:948-953.
27. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029-2036.
28. Chenevert TL, Meyer CR, Moffat BA, et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging. 2002;1:336-343.
29. Herneth AM, Friedrich K, Weidekamm C, et al. Diffusion weighted imaging of bone marrow pathologies. Eur J Radiol. 2005;55:74-83.
30. Jacobs MA, Herskovits EH, Kim HS. Uterine fibroids: diffusion-weighted MR imaging for monitoring therapy with focused ultrasound surgery - preliminary study. Radiology. 2005;236:196-203.
31. Jacobs MA, Pan L, Macura K. Whole-body diffusion weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer. Semin Roentgenol. 2009;44:111-122.
32. Jacobs MA, Ouwerkerk R, Kamel I, et al. Proton, diffusion-weighted imaging, and sodium ((23)Na) MRI of uterine leiomyomata after MR-guided high-intensity focused ultrasound: a preliminary study. J Magn Reson Imaging. 2009;29:649-656.
33. Le Bihan D, Breton E, Lallemand D, et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401-407.
34. Le Bihan D, Breton E, Lallemand D, et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988;168:497-505.
35. Szafer A, Zhong J, Gore JC. Theoretical model for water diffusion in tissues. Magn Reson Med. 1995;33:697-712.
36. Babsky AM, Topper S, Zhang H, et al. Evaluation of extra- and intracellular apparent diffusion coefficient of sodium in rat skeletal muscle: effects of prolonged ischemia. Magn Reson Med. 2008; 59:485-491.
37. Jacobs MA, Ouwerkerk R, Wolff AC, et al. Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. Technol Cancer Res Treat. 2004;3:543-550.
38. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006;17:505-512.
39. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004;20:654-661.
40. Herneth AM, Philipp MO, Naude J, et al. Vertebral metastases: assessment with apparent diffusion coefficient. Radiology. 2002;225:889-894.
41. Knight RA, Ordidge R, Helpern J, et al. Temporal evolution of ischemic damage in rat brain measured by proton nuclear magnetic resonance imaging. Stroke. 1991;22:802-808.
42. Jacobs MA, Mitsias P, Soltanian-Zadeh H, et al. Multiparametric MRI tissue characterization in clinical stroke with correlation to clinical outcome: part 2. Stroke. 2001;32:950-957.
43. Le Bihan DJ. Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: a closer step toward the "holy grail" of tissue characterization? Radiology. 1998;207:305-307.
44. Zelhof B, Lowry M, Rodrigues G, et al. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. BJU Int. 2009.
45. Desouza NM, Reinsberg SA, Scurr ED, et al. Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol. 2007;80:90-95.
46. Brunberg JA, Chenevert TL, McKeever PE, et al. In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol. 1995;16:361-371.
47. Gibbs P, Tozer DJ, Liney GP, et al. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054-1058.
48. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging. 2002;16:196-200.
49. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol. 2006;41:185-188.
50. Pickles MD, Gibbs P, Sreenivas M, et al. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging. 2006;23:130-134.
51. 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol. 2007;188:91-98.
52. Gibbs P, Pickles MD, Turnbull LW. Repeatability of echo-planarYbased diffusion measurements of the human prostate at 3 T. Magn Reson Imaging. 2007;25:1423-1429.
53. Kim CK, Park BK, Lee HM, et al. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol. 2007;42:842-847.
54. 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology. 2008;246:480-488.
55. Chen M, Dang HD, Wang JY, et al. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol. 2008;49:602-610.
56. Kozlowski P, Chang SD, Goldenberg SL. Diffusion-weighted MRI in prostate cancer - comparison between single-shot fast spin echo and echo planar imaging sequences. Magn Reson Imaging. 2008;26:72-76.
57. Gurses B, Kabakci N, Kovanlikaya A, et al. Diffusion tensor imaging of the normal prostate at 3 tesla. Eur Radiol. 2008;18:716-721.
58. Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging. 2008;27: 132-139.
59. Ren J, Huan Y, Wang H, et al. Diffusion-weighted imaging in normal prostate and differential diagnosis of prostate diseases. Abdom Imaging. 2008;33:724-728.
60. Tamada T, Sone T, Toshimitsu S, et al. Age-related and zonal anatomical changes of apparent diffusion coefficient values in normal human prostatic tissues. J Magn Reson Imaging. 2008;27:552-556.
61. Van As N, Charles-Edwards E, Jackson A, et al. Correlation of diffusion-weighted MRI with whole mount radical prostatectomy specimens. Br J Radiol. 2008;81:456-462.
62. deSouza NM, Riches SF, Vanas NJ, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol. 2008;63: 774-782.
63. Jagannathan NR, Kumar V, Kumar R, et al. Role of magnetic resonance methods in the evaluation of prostate cancer: an Indian perspective. MAGMA. 2008;21:393-407.
64. Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int. 2008.
65. Riches SF, Hawtin K, Charles-Edwards EM, et al. Diffusion-weighted imaging of the prostate and rectal wall: comparison of biexponential and monoexponential modelled diffusion and associated perfusion coefficients. NMR Biomed. 2009;22:318-325.
66. Lim HK, Kim JK, Kim KA, et al. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection - a multireader study. Radiology. 2009;250:145-151.
67. Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging. 2009;29:391-397.
68. Xu J, Humphrey PA, Kibel AS, et al. Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med. 2009;61:842-850.
69. Kozlowski P, Chang SD, Jones EC, et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis - correlation with biopsy and histopathology. J Magn Reson Imaging. 2006;24:108-113.
70. Mulkern RV, Vajapeyam S, Robertson RL, et al. Biexponential apparent diffusion coefficient parametrization in adult vs newborn brain. Magn Reson Imaging. 2001;19:659-668.
71. Chan I, Wells W 3rd, Mulkern RV, et al. Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted magnetic resonance imaging; a multichannel statistical classifier. Med Phys. 2003;30:2390-2398.
72. Padhani AR, Liu G, Mu-Koh D, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102-125.
73. Bastin ME, Le Roux P. On the application of a non-CPMG single-shot fast spin-echo sequence to diffusion tensor MRI of the human brain. Magn Reson Med. 2002;48:6-14.
74. Gudbjartsson H, Maier SE, Mulkern RV, et al. Line scan diffusion imaging. Magn Reson Med. 1996;36:509-519.
75. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol. 2007;61:297-302.
76. Scheenen TW, Heijmink SW, Roell SA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology. 2007;245:507-516.
77. Barker PB, Hearshen DO, Boska MD. Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med. 2001;45:765-769.
78. Pruessmann KP, Weiger M, Scheidegger MB, et al. SENSE: sensitivity encoding for fast MRI. Magn Reson Med. 1999;42:952-962.
79. Sodickson DK, Manning WJ. Simultaneous acquisition of spatial harmonics (SMASH): fast imaging with radiofrequency coil arrays. Magn Reson Med. 1997;38:591-603.
80. Griswold MA, Jakob PM, Heidemann RM, et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med. 2002;47:1202-1210.
81. Heerschap A, Jager GJ, van der Graaf M, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997;17:1455-1460.
82. Leach MO, Verrill M, Glaholm J, et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized P-31 measurements of response to treatment. NMR Biomed. 1998;11:314-340.
83. Jacobs MA, Barker PB, Bottomley PA, et al. Proton MR spectroscoptic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging. 2004;19:68-75.
84. 1H MR spectroscopy - a pilot study at 4 T. Radiology. 2004;233:424-431.
85. Manton DJ, Chaturvedi A, Hubbard A, et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer. 2006;94:427-435.
86. Cooper JF, Imfeld H. The role of citric acid in the physiology of the prostate: a preliminary report. J Urol. 1959;81:157-164.
87. Yacoe ME, Sommer G, Peehl D. In vitro proton spectroscopy of normal and abnormal prostate. Magn Reson Med. 1991;19:429-438.
88. Schick F, Bonger H, Kurz S, et al. Localized proton MR spectroscopy of citrate in vitro and of the human prostate in vivo at 1.5 T. Magn Reson Med. 1993;29:38-43.
89. Cheng LL, Chang IW, Smith BL, et al. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson. 1998;135:194-202.
90. Mountford C, Lean C, Malycha P, et al. Proton spectroscopy provides accurate pathology on biopsy and in vivo. J Magn Reson Imaging. 2006;24:459-477.
91. Costello LC, Franklin RB, Narayan P. Citrate in the diagnosis of prostate cancer. Prostate. 1999;38:237-245.
92. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 1987;508:333-348.
93. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999;12: 413-439.
94. 1H MR spectroscopic imaging findings - initial observations. Radiology. 2004;231:717-724.
95. Schiebler ML, Miyamoto KK, White M, et al. High resolution spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn Reson Med. 1993;29:285-291.
96. Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995;45:459-466.
97. 3) spatial resolution. Radiology. 1996;198:795-805.
98. Prando A, Billis A. Focal prostatic atrophy: mimicry of prostatic cancer on TRUS and 3D-MRSI studies. Abdom Imaging. 2009;34:271-275.
99. de Graaf R. In Vivo NMR Spectroscopy: Principles and Techniques. New York, NY: Wiley-Interscience; 2007:592.
100. 1H MRS localization sequences. J Magn Reson B. 1995;107:25-33.
101. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129:35-43.
102. Trabesinger AH, Meier D, Dydak U, et al. Optimizing PRESS localized citrate detection at 3 tesla. Magn Reson Med. 2005;54:51-58.
103. 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med. 2005;53:1268-1274.
104. Lange T, Trabesinger AH, Schulte RF, et al. Prostate spectroscopy at 3 tesla using two-dimensional S-PRESS. Magn Reson Med. 2006;56: 1220-1228.
105. Gabr RE, Ouwerkerk R, Bottomley PA. Quantifying in vivo MR spectra with circles. J Magn Reson. 2006;179:152-163.
106. Star-Lack J, Nelson SJ, Kurhanewicz J, et al. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med. 1997;38:311-321.
107. Ouwerkerk R, Edden RA. Multi-Band Adiabatic Pulses. Seattle, WA; Proceedings of the ISMRM; 2006;14:3006.
108. Jung JA, Coakley FV, Vigneron DB, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology. 2004;233:701-708.
109. Umbehr M, Bachmann LM, Held U, et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol. 2008.
110. Klomp DW, Bitz AK, Heerschap A, et al. Proton spectroscopic imaging of the human prostate at 7 T. NMR Biomed. 2009.
111. Jorgensen T, Muller C, Kaalhus O, et al. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2). Eur Urol. 1995;28:40-46.
112. Imbriaco M, Larson SM, Yeung HW, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res. 1998;4:1765-1772.
113. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942-2953.
114. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379.
115. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431-1434.
116. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233: 139-148.
117. Takahara T, Imai Y, Yamashita T, et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004;22:275-282.
118. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment - utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008;248:643-654.
119. Sella A, Sternberg CN, Skoneczna I, et al. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int. 2008;102:1607-1609.
120. Sinha S, Sinha U. In vivo diffusion tensor imaging of the human prostate. Magn Reson Med. 2004;52:530-537.
121. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging. 2005;21:258-262.
122. Manenti G, Squillaci E, Di Roma M, et al. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging. Radiol Med. 2006;111: 1124-1133.
123. Matsuki M, Inada Y, Tatsugami F, et al. Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur Radiol. 2007;17: 201-204.
124. Kitajima K, Kaji Y, Kuroda K, et al. High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-to-noise ratio. Magn Reson Med Sci. 2008;7:93-99.
125. Takayama Y, Kishimoto R, Hanaoka S, et al. ADC value and diffusion tensor imaging of prostate cancer: changes in carbon-ion radiotherapy. J Magn Reson Imaging. 2008;27:1331-1335.
126. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2 - sparse versus dense cancers. Radiology. 2008;249:900-908.
127. Kumar V, Jagannathan NR, Kumar R, et al. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed. 2007;20:505-511.
128. Tanimoto A, Nakashima J, Kohno H, et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging. 2007;25:146-152.
129. Kim JH, Kim JK, Park BW, et al. Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging. 2008;28:1173-1179.
130. Kurhanewicz J, Vigneron DB, Hricak H, et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology. 1996;200:489-496.
131. Parivar F, Hricak H, Shinohara K, et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology. 1996;48:594-599.
132. Heerschap A, Jager GJ, Van Der Graaf M, et al. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med. 1997;37:204-213.
133. Kim JK, Kim DY, Lee YH, et al. In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: localized proton magnetic resonance spectroscopy using external-body surface coil. Magn Reson Imaging. 1998;16:1281.
134. Kaji Y, Kurhanewicz J, Hricak H, et al. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology. 1998;206:785-790.
135. Garcia-Segura JM, Sanchez-Chapado M, Ibarburen C, et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magn Reson Imaging. 1999;17:755-765.
136. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology. 1999;213:473-480.
137. Males RG, Vigneron DB, Star-Lack J, et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med. 2000; 43:17-22.
138. 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology. 2001;221:380-390.
139. Kaji Y, Wada A, Imaoka I, et al. Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil. J Magn Reson Imaging. 2002;16:697-706.
140. Zakian KL, Eberhardt S, Hricak H, et al. Transition zone prostate cancer: metabolic characteristics at H MR spectroscopic imaging - initial results. Radiology. 2003;229:241-247.
141. Squillaci E, Manenti G, Mancino S, et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res. 2005; 24:523-530.
142. 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur Radiol. 2005;15: 645-652.
143. Kumar V, Jagannathan NR, Kumar R, et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging. 2006;24:541-548.
144. Shukla-Dave A, Hricak H, Moskowitz C, et al. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology. 2007;245:499-506.
145. Cirillo S, Petracchini M, Della Monica P, et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol. 2008;63:871-879.
146. Thomas MA, Lange T, Velan SS, et al. Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo. MAGMA. 2008;21:443-458.
147. Ren FY, Lu JP, Wang J, et al. Adult prostate sarcoma: radiological clinical correlation. Clin Radiol. 2009;64:171-177.